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Abstract
Introduction: Statins reportedly have anti-inflammatory and anti-thrombotic effects aside from cholesterol-
lowering. This study aimed to evaluate the effect of pre-existing statin use on platelet activation markers and
clinical outcome in acute ischemic stroke patients.
Methods: This prospective study evaluated 172 patients with acute ischemic stroke divided in two groups: patients
with pre-existing statin (n = 43) and without pre-existing statin (66 cases with statins initiated post-stroke and 63
without statin treatment). Platelet activation markers (CD62P and CD63) were measured by flow cytometry at
different time points after stroke and analyzed with clinical outcome.
Results: The CD62P and CD63 expressions on platelets were significantly lower in the patients with pre-existing
statin use compared to the patients without pre-existing statin use on Day 1 post-stroke (p < 0.05). The CD62P
expression was significantly lower in the patients with pre-existing statin use on 90 days after the acute stroke (p <
0.05). Patients with pre-existing statin use had lower incidences of early neurologic deterioration (END) than those
without treatment (p < 0.05). Among several baseline clinical variables, admission NIHSS score, history of coronary
artery disease, and pre-existing statin use were independent predictions of good clinical outcome at three months.
Conclusions: Pre-existing statin use is associated with decreased platelet activity as well as improved clinical
outcome and reduced END in patients with acute ischemic stroke.
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Introduction
Stroke is a major cause of morbidity and one of the lead-
ing causes of death worldwide [1]. Atherothrombosis and
inflammation play important roles in the pathogenesis of
acute ischemic stroke [2-4]. A previous study demon-
strates that platelet activity, measured by CD62P and
CD63 expressions on platelets, are increased after acute
ischemic stroke and reduced in patients who receive anti-
platelet therapy [5-7]. Anti-platelet drugs are the most
commonly used drugs for secondary prevention after
ischemic stroke of non-cardio-embolic origin [8], but
their efficacy is not completely satisfactory [9,10].
Statins, the 3-hydroxy 3-methyl-glutaryl coenzyme-A
(HMG-CoA) reductase inhibitors, are medications ori-
ginally used for the control of hypercholesterolemia [11].
However, there is increasing evidence that statins have
anti-inflammatory and anti-thrombotic effects aside from
their cholesterol-lowering effect [12,13]. Statin therapy
has been shown to reduce cardiovascular events, includ-
ing myocardial infarction, stroke, and death [14-16].
Moreover, early statin treatment may reduce the severity
and improve the outcome of myocardial infarction,
ischemic stroke, and intra-cerebral hemorrhage [17-20].
Although statin therapy is widely used in patients
at high-risk for major vascular events, the benefits of
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pre-existing statin therapy in patients with acute ischemic
stroke remain controversial. Multiple studies have demon-
strated improved clinical outcomes in patients taking
statins at stroke onset [18,19]; however, mechanisms con-
ferring this protection have not been well studied. Thus,
this prospective cohort study aimed to test the difference
in platelet activity between patients taking statins before
and after acute ischemic stroke by assessing CD62P and
CD63 expression. This study also analyzed if prior statin
treatment could reduce the neurologic deterioration and




Consecutive patients with acute ischemic stroke admitted
to the Department of Neurology of Chang Gung Memorial
Hospital-Kaohsiung, Taiwan, from August 2009 to July
2010 were evaluated. Acute ischemic stroke was defined as
acute-onset loss of focal cerebral function persisting for at
least 24 hours. The diagnosis of stroke was made based on
clinical presentation, neurologic examination, and results
of brain magnetic resonance imaging (MRI) with magnetic
resonance angiography (MRA). Patients with cardio-
embolic stroke were excluded, as well as those with under-
lying neoplasm, vasculitis, hematologic disorders that
affect platelet count or function, end-stage renal disease,
liver cirrhosis, and congestive heart failure. As pathogen-
esis and treatment could be different between patients
with cardio-embolic and non-cardio-embolic ischemic
stroke, those with cardio-embolism were excluded by clin-
ical presentation, ECG, and cardiac ultrasound, while
those who received intravenous thrombolytic therapy were
also excluded.
To avoid the confounding factor of anti-platelet thera-
pies or dosage effects on measured platelet activity, all
patients taking one or more anti-platelet medication (e.g.
aspirin, dipyradimole, or clopidogrel) prior to stroke
onset were excluded from enrollment. All enrolled
patients were treated with aspirin (100 mg/day) therapy
post-stroke. The Institutional Review Committee on
Human Research approved the study protocol and the
participating subjects provided informed consent.
Demographic data, history of risk factors (i.e., hyper-
tension, diabetes mellitus, dyslipidemia, cigarette smok-
ing, and cardiovascular disease), and history of previous
vascular events (i.e., myocardial infarction, angina, old
stroke history) were obtained at baseline. Vascular risk
factors included hypertension, blood pressure above 140/
90 mmHg at two readings or use of anti-hypertensives;
diabetes mellitus (DM), elevated blood glucose at two
recordings, elevated hemoglobin A1c (HbA1c) or use of
anti-diabetics; and dyslipidemia, total cholesterol above
200 mg/dL, triglycerides above 180 mg/dL or use of
lipid-lowering medication [10].
Of the 220 patients with acute non-cardio-embolic
ischemic stroke, 30 were excluded due to previous anti-
platelet therapy before the stroke, six due to cardio-
embolic stroke (e.g. paroxysmal atrial fibrillation on EKG),
four due to hemorrhagic transformations of ischemic
strokes on the first brain imaging, four with end-stage
renal disease, and four with gastro-intestinal bleeding in
the acute stage. The remaining 172 patients were classified
into two groups: patients with pre-existing statin use
(patients taking statins prior to stroke onset) and patients
without pre-existing statin use (patients did not take sta-
tins prior to stroke onset). For further comparison, the
patients without pre-existing statin use were divided to
two sub-groups: the statin-initiated group (patients placed
on statins after stroke onset) and the non-statin treatment
group (patients not placed on statins before and after
stroke onset).
The lipid-lowering regimens used for preventing
ischemic stroke were according to the American Heart
Association/American Stroke Association guidelines for
diabetic or high-risk patients and included statins if the
low density lipoprotein (LDL) was above 70 and in non-
diabetics if the LDL was above 100 [21]. The etiologic
sub-types of i schemic stroke were classified according
to the TOAST (Trial of Org 10172 in Acute Stroke
Treatment) criteria [22].
Clinical assessments
Detailed medical history was obtained from patients and
their families whenever possible, with specific standar-
dized questioning regarding prior use of drugs. All of the
patients underwent complete neurologic examination
upon enrollment and on follow up. Brain MRI with
MRA, extra-cranial carotid sonography, and trans-cranial
color-coded sonography were performed on ischemic
stroke patients during hospitalization. Early neurologic
deterioration (END) was defined as an increase of four or
more points in National Institutes of Health Stroke Scale
(NIHSS) during hospitalization [23]. Follow-up brain CT
scans were performed if END was noted, including
hemorrhagic transformation (hyperdense signal over the
infarction area), enlarged cerebral infarction (increased
area of original lower attenuation or new infarction
lesions), and cerebral edema (abnormal hypodense signal
surrounding the infarction area with sulcal effacement or
mass effect) [24].
Neurologic deficits due to stroke were assessed using
the NIHSS. Physical disability and handicap were evalu-
ated using the Barthel index (BI) and modified Rankin
Scale (mRS). Therapeutic outcomes were evaluated
three months post-stroke and good outcome was
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defined as a three-month mRS of 0 to 2, while poor out-
come was mRS of 3 to 6.
Blood sampling and assessment of platelet activity
Blood samples were collected by venipuncture of the fore-
arm veins in acute stroke patients within 48 hours and on
days 7 and 30 post-stroke. Flow cytometry for platelet
activity markers was performed as previously described
[7]. Platelet activity was assessed using platelet activation
markers (CD62P and CD63). Briefly, sodium citrate con-
taining blood was centrifuged for 15 minutes at 1,500 rpm
at room temperature. The samples were incubated with
saturating concentrations of phycoerythrin (PE)-labeled
antibodies (Becton Dickinson Biosciences, CA, USA.)
against CD62P (clone AK-4) and CD63 (Clone H5C6)
with fluorescein isothiocyanate-labeled antibodies against
CD61 (clone VI-PL2) for 30 minutes at room temperature
in the dark. For control experiments, platelets were incu-
bated with PE-coupled unspecific mouse IgG1 (Becton
Dickinson Biosciences, CA, USA.) with the same ratio and
concentration of fluorochrome-to-protein as specific IgG.
After immuno-labeling, the samples were analyzed by
Coulter Epics XL flow cytometry (Beckman Coulter,
Miami, USA.). Forward light scatter and CD61 expression
were used for platelet identification. Platelet-bound anti-
CD62P and anti-CD63 antibodies were determined by
analyzing 10,000 platelets for PE-positive fluorescence.
Results were presented as percentages of antibody-posi-
tive platelets. Intra-assay variability based on repeated
measurements of the same blood sample was low, with
mean coefficients of variance of 7.5% (< 48 hours), 7.3%
(day 7), and 6.9% (day 30) for stroke patients.
Statistical analysis
Data were presented as mean ± standard error of the
mean and as comparisons between groups. Continuous
variables, including age, cell counts, lipid profile, HbA1c,
blood pressure, and CD62P and CD63 levels were ana-
lyzed by independent t-test between groups. The NIHSS
score between the two groups were analyzed by the
Mann-Whitney U test. Chi-square test or Fisher’s exact
test were used to compare proportions between the two
patient groups. Repeated measures of ANOVA were used
to compare platelet activity at different time points (< 48
hours and on Days 7 and 30 post-stroke), while Scheffe’s
multiple comparison analyzed the intra-individual course
of parameters over time and compared the parameters of
two different groups.
The independent t-test was used to compare the good
and poor outcome groups. Multiple logistic regression
analyses were used to determine the independent influ-
ence of different predictive variables on clinical outcome.
The variables considered were age, gender, lipid profiles,
coronary artery diseases, NIHSS score, pre-existing statin
use, the levels of CD62P and CD63. A p < 0.05 was con-
sidered statistically significant. All statistical calculations
were performed using the SAS software package, version
9.1 (2002, SAS Statistical Institute, Cary, North Carolina).
Ethics approval
The study was approved by Chang Gung Memorial Hos-
pital’s Institutional Review Committee on Human
Research.
Results
Baseline characteristics between the patient groups
The group with pre-existing statin use had 43 patients
whereas the group without pre-existing statin use had 129.
Of these 129 patients, 66 were given statins after the stroke
onset (statin-initiated group) and 63 were not given statins
at all (non-statin treatment group). In patients with pre-
existing statin use, 17 used atorvastatin (10 to 20 mg/d), 11
used fluvastatin (80 mg/d), 12 used rosuvastatin (5 to
10 mg/d), and 3 used simvastatin (10 to 40 mg/d). All of
the patients with pre-existing statin use took statins for
more than seven days and the final dose of statins was
24 hours before the onset of symptoms. In the statin-
initiated group, 18 used atorvastatin (10 to 20 mg/d),
15 used fluvastatin (80 mg/d), 25 used rosuvastatin (5 to
10 mg/d), and 8 used simvastatin (10 to 40 mg/d). They all
took the first dose of statin within 72 hours after stroke
onset.
The demographic data of the study patients are shown
in Table 1. The history of DM was significantly different
between the two groups but there were no significant
differences in age, sex, other vascular risk factors, and
stroke sub-types. The median (inter-quartile range)
NIHSS score on admission was significantly lower in
patients with pre-existing statin use than those without
pre-existing statin use (p < 0.05).
Laboratory data were presented in Table 2. Serum
total cholesterol, LDL-cholesterol, and triglyceride were
significantly lower in patients with pre-existing statin
use than those without pre-existing statin use. There
were no significant differences between the two groups
in terms of white blood cell (WBC), red blood cell
(RBC) and platelet counts, HbA1c, prothrombin time
(PT), activated partial thromboplastin time (APTT),
high density lipoprotein (HDL)-cholesterol, and systolic
and diastolic blood pressure. The CD62P and CD63
expressions on platelets were significantly lower in
patients with pre-existing statin use than those without
pre-existing statin use (p < 0.05).
Serial changes in platelet activation markers between
groups
Expressions of CD62P between the patients with pre-
existing statin use and without pre-existing statin use
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are shown in Figure 1. The percentage of platelets
expressing CD62P was significantly lower in the patients
with pre-existing statin used group on day 1 compared
with those without pre-existing statin use. Although
CD62P levels declined gradually in two groups, platelet
CD62P levels were still significantly lower in patients
with pre-existing statin use 90 days after the acute
stroke (p < 0.05). Repeated analysis of variance
(ANOVA) with Scheffe’s multiple comparison showed
that CD62P expressions between the two groups at four
different time points (< 48 hours and on days 7, 30, and
90 post-stroke) were significantly different (p < 0.05).
Expressions of CD63 between the patients with pre-
existing statin use and those without pre-existing statin
use are shown in Figure 2. The percentage of platelets
expressing CD63 was significantly lower in patients with
pre-existing statin use on day 1 than those without pre-
existing statin use. However, there was no significant
difference after day 7 post-stroke. Repeated measures
comparison showed that CD63 expressions between the
two groups at different time points were not different.
Expression of CD62P and CD63 between the statin-
initiated and non-statin treatment groups are shown in
Figures 3 and 4, respectively. The percentage of platelets
expressing CD62P or CD63 was not different between
the two sub-groups from days 1 to 90. Repeated mea-
sures comparison of CD62P or CD63 expressions at dif-
ferent time points were also not different between the
two sub-groups.
Predictive factors for three-month outcome
Potential prognostic factors of the 172 acute stroke
patients for three-month outcome are listed in Table 3.
Although no patient died during the follow-up period,
133 had good outcomes and 39 had poor outcomes. Sta-
tistical analysis revealed that history of coronary artery
Table 1 Baseline characteristics of stroke patients in the two groups
With pre-existing statin use (n = 43) Without pre-existing statin use (n = 129) P value
Age (years) (mean ± SEM) 67.5 ± 1.4 64.0 ± 1.2 0.43
Male (%) 69.8 60.6 0.41
Hypertension (%) 83.7 74.2 0.39
Diabetes mellitus (%) 58.1 31.8 0.01
Coronary artery diseases (%) 7.0 3.0 0.37
Intracranial atherosclerosis (%) 30.2 24.2 0.64
Stroke subtype
Small-vessel disease 51.3 60.0 0.42
Large-vessel disease 48.7 40.0
Median NIHSS (IQR) scores on admission 4 (2.0-7.0) 5 (2.5-7.75) 0.03
IQR, inter-quartile range; NIHSS, National Institutes of Health Stroke Scale; SEM, standard error of the mean.
Table 2 Baseline laboratory data of stroke patients in the two groups
With pre-existing statin use (n = 43) Without pre-existing statin use (n = 129) P value
White blood cells (X103/ml) 7.5 ± 0.4 7.5 ± 0.3 0.86
Red blood cells (X106/ml) 4.6 ± 0.1 4.7 ± 0.1 0.71
Platelet counts (X104/ml) 20.2 ± 1.1 21.9 ± 0.7 0.43
Total cholesterol (mg/dl)† 148.3 ± 4.3 218.8 ± 6.5 < 0.0001
LDL-cholesterol (mg/dl)† 83.0 ± 3.7 142.9 ± 5.1 < 0.0001
HDL-cholesterol (mg/dl)† 40.3 ± 1.6 42.8 ± 1.5 0.27
Triglyceride (mg/dl) 125.3 ± 8.3 176.3 ± 14.7 0.04
HbA1c (%) 7.3 ± 0.3 7.1 ± 0.3 0.43
APTT (second) 28.0 ± 0.5 27.9 ± 0.4 0.91
PT (second) 10.2 ± 0.1 10.1 ± 0.1 0.37
Systolic BP (mmHg) 138.7 ± 2.4 146.6 ± 2.4 0.13
Diastolic BP (mmHg) 80.1 ± 1.3 85.2 ± 1.6 0.10
CD62P (%)† 2.2 ± 0.6 3.9 ± 0.5 0.01
CD63 (%)† 1.2 ± 0.2 1.8 ± 0.5 0.03
APTT, activated partial thromboplastin time; BP, blood pressure; HbA1c, hemoglobin A1c; HDL, high density lipoprotein; LDL, low density lipoprotein; PT,
prothrombin time.
† The data was expressed as primitive data, and the P value was obtained from those primitive data that were logarithmically transformed to improved normality
and compared by independent -t test.
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diseases, NIHSS score on admission, pre-existing statin
use, and platelet activation markers (CD62P and CD63)
were significantly different between the good and poor
outcome groups. Variables used in the stepwise logistic
regression model included underlying age, gender, lipid
profiles, coronary artery diseases, NIHSS score, pre-
existing statin use, and CD62P and CD63 levels. After
analysis, only NIHSS score (odds ratio (OR) = 1.10, 95%
confidence interval (CI) = 1.03-1.17; P = 0.007), underly-
ing coronary artery diseases (OR = 0.05, 95% CI = 0.01-
0.38; P = 0.003), and pre-existing statin use (OR = 4.82,
95% CI = 1.22-19.03; P = 0.025) were independently
associated with three-month outcome.
Early neurologic deterioration and statin therapy
Of 172 acute ischemic patients, 14 suffered from END
while hospitalized during the study period. Of the 14
END patients, four had hemorrhagic transformation, five
had larger cerebral infarction, and five had increased of
cerebral edema by follow-up brain CT. Patients with sta-
tin treatment after acute stroke (e.g. pre-existing statin
use and statin-initiated groups) had significantly lower
incidence of END (5 in 109 cases) compared with those
without statin treatment (9 in 63 cases; p < 0.05).
Furthermore, statin initiation after acute stroke also had
significantly lower incidence of END (1 in 66 cases)
compared with those without statin treatment (9 in 63
cases; P = 0.008).
Discussion
The present study examined the expression of serial pla-
telet activation markers (CD62P and CD63) and the
three-month outcome after acute non-cardio-embolic
ischemic stroke and produced four major findings. First,
the severity of the initial stroke (NIHSS score on admis-
sion) is relatively low in patients with statin treatment
before stroke onset. Second, CD62P and CD63 expres-
sions in platelets on admission are significantly lower in
patients with pre-existing statin use than those without
pre-existing statin use. Furthermore, CD62P expressions
between groups at four different time points (< 48
hours and on days 7, 30, and 90) are significantly differ-
ent (p < 0.05). Third, underlying coronary artery dis-
eases, NIHSS score on admission, and pre-existing statin
use are independently associated with three-month out-
come. Finally, patients with statin treatment in the acute
Figure 1 Serial changes of the percentages of CD62P
expression in platelets between patients with pre-existing
statin use and those without pre-existing statin use after acute
ischemic stroke. *p < 0.05 patients with pre-existing statin use
compared with patients without pre-existing statin use.
Figure 2 Serial changes of the percentages of CD63 expression
in platelets between patients with pre-existing statin use and
those without pre-existing statin use after acute ischemic
stroke. *p < 0.05 patients with pre-existing statin use compared
with patients without pre-existing statin use.
Figure 3 Serial changes of the percentages of CD62P
expression in platelets between statin initiated group and
non-statin treated group after acute ischemic stroke.
Figure 4 Serial changes of the percentages of CD63 expression
in platelets between statin initiated group and non-statin
treated group after acute ischemic stroke.
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phase of stroke have significantly lower incidences of
END compared with those without statin treatment.
In the current study, platelet activation levels differed
between the statin groups. However, they did not signifi-
cantly predict good outcome. In contrast, statin use or
non-use did predict outcome. This suggests that either
platelet activity detected in vitro by flow cytometry may
not actually reflect the in vivo platelet effects of statins,
or that statins improve outcome via other mechanisms.
The mechanisms by which statins benefit patients with
acute ischemic stroke remain unclear and are likely to be
multi-factorial. Increasing evidence shows that statins
have pleiotropic effects beyond their lipid-lowering
effects [25]. Statins interfere with platelet aggregation
and have anti-inflammatory, anti-oxidative, and anti-
apoptotic properties [26-29]. Previous studies have
demonstrated that platelet aggregation and leukocyte
activity are significantly increased after ischemic stroke
and contribute to the severity of brain damage [4,30].
The present study is the first to demonstrate that platelet
activation markers (CD62P and CD63) are significantly
inhibited in patients taking statins prior to an acute non-
cardio-embolic ischemic stroke. These results are consis-
tent with those of previous studies and further corrobo-
rate the anti-platelet effect of statins [31]. This anti-
platelet effect may be via improved endothelial function
and increased systemic nitric oxide bioavailability that
inhibits exaggerated platelet activation [26].
There is mounting evidence that statin therapy may
alter vascular atherosclerosis and reduce cardiovascular
events, including myocardial infarction, stroke, and death
[13,14,32]. The JUPITER study further demonstrates that
rosuvastatin significantly reduces the incidence of major
cardiovascular events in apparently healthy persons with-
out hyperlipidemia but with elevated high-sensitivity C-
reactive protein levels [33]. Furthermore, the abrupt
withdrawal of statin therapy may increase the risk of car-
diovascular events and death because of rebound of
inflammatory response [23,34,35].
Recent studies also show that prior or early use of sta-
tins may reduce the severity and improve the outcome of
myocardial infarction, ischemic stroke, and intra-cerebral
Table 3 Prognostic factors of patients with acute ischemic stroke
Good outcome (n = 133) Poor outcome (n = 39) P value
Age (year)
Sex (female) (%) 32.3 46.2 0.11
Hypertension (%) 77.4 84.6 0.33
Diabetes mellitus (%) 38.3 48.7 0.25
Hyperlipidemia (%) 50.4 38.5 0.19
Coronary artery disease (%) 1.5 12.8 0.002
Intra-cranial atherosclerosis (%) 23.3 30.8 0.34
Stroke sub-type
Small vessel disease (%) 57.1 48.7 0.24
Large vessel disease (%) 39.1 51.3
Statin therapy groups
Pre-existing statin use (%) 29.3 10.3 0.016
Median NIHSS (IQR) scores on admission 3 (1-5) 4 (3-8) 0.009
Laboratory data on admission
White blood cells (X103/ml) 7.5 ± 0.2 7.6 ± 0.4 0.69
Red blood cells (X106/ml) 4.6 ± 0.1 4.6 ± 0.1 0.73
Platelet counts (X104/ml) 21.2 ± 0.6 19.5 ± 0.7 0.06
Total cholesterol (mg/dl) 183.0 ± 4.2 187.8 ± 8.5 0.61
LDL-cholesterol (mg/dl) 113.7 ± 3.7 114.3 ± 6.7 0.93
Triglyceride (mg/dl) 143.1 ± 7.8 147.2 ± 8.5 0.82
HbA1c (%) 7.0 ± 0.2 7.4 ± 0.4 0.33
Systolic BP (mmHg) 143.4 ± 1.8 140.6 ± 3.5 0.46
Diastolic BP (mmHg) 83.8 ± 1.1 82.8 ± 2.1 0.67
Platelet markers on admission
CD62P (%)† 3.45 ± 0.38 5.39 ± 0.89 0.024
CD63 (%)† 1.41 ± 0.12 1.99 ± 0.31 0.035
Good outcome, three-month mRS (0 to 2); poor outcome, three-month modified Rankin Scale (3 to 6).
BP, blood pressure; HbA1c, hemoglobin A1c; IQR, inter-quartile range; LDL, low density lipoprotein; NIHSS, National Institutes of Health Stroke Scale;
† The data was expressed as primitive data, however, the p value was obtained from logarithmically transformed of primitive data to improved normality.
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hemorrhage [17-20]. Consistent with previous research,
the current study reveals that pre-treatment with statins
may be associated with reduced clinical severity and
favorable three-month outcome in patients with acute
ischemic stroke. Recent clinical research demonstrates
that high CD62P and CD40L expressions on admission
are strongly associated with poor clinical outcomes after
acute ischemic stroke [36]. Therefore, stronger inhibition
of platelet activity in the acute phase of ischemic stroke
may be beneficial in improving clinical outcome.
The causes of END after acute ischemic stroke remain
unknown but may be related to hemorrhagic transfor-
mation, progression of cerebral infarction, or cerebral
edema. Previous researchers hypothesize that early leu-
kocyte-endothelium interaction and substantial inflam-
matory reaction may play important roles in patients
with stroke in progression [4,19]. In the current study,
although the causes of END are heterogeneous between
groups, statin treatment in the acute phase of stroke
reduces the incidence of END compared with those
without statin treatment after stroke. Because of the
limitations of case number and study design, the role of
statin therapy in END cannot be explained.
This study has several limitations. First, this is an
observational study and it is possible that unmeasured
or unknown confounders may have influenced the
results. Second, although patients with prior anti-platelet
therapy before acute stroke have been excluded, the
expression of the platelet activation markers may be
influenced by other drugs (e.g. beta-blocker, ACE inhibi-
tors, and calcium channel blockers) that may cause
potential bias in the statistical analysis [37]. Third,
whether any particular statin or dosage has superior
effects has not been tested because of the relatively
small number of patients. Fourth, the baseline NIHSS is
lower in the pre-existing statin use group. This may be
based on very early effects of statins (such as increased
perfusion and tissue salvage/collateral flow, which would
be plausible if NIHSS measurement was performed at
12 hours after stroke onset) or may represent an imbal-
ance in stroke severity between the two groups suggest-
ing a bias of study design because it is not randomized.
Fifth, patients with cardio-embolic stroke were excluded
from this study according to medical history, ECG, and/
or echocardiography. Thus, the effect of statin pre-treat-
ment in patients with cardio-embolic stroke was unclear.
Finally, this is a cohort study in a single-center with a
relatively small patient number. Thus, it is possible that
there is a smaller-than-expected magnitude of the pro-
tective effects exerted by statins. Randomized, larger-
scale trials are warranted to establish whether early sta-
tin therapy has important beneficial effects in patients
with acute ischemic stroke.
Conclusions
Statin therapy in acute non-cardio-embolic ischemic
stroke can improve the three-month outcome and pre-
vent END through potential anti-platelet effects. More
prospective, longitudinal observational studies are war-
ranted to evaluate the relation between dosage and
choice of different statins in treating non-cardio-embolic
stroke patients, to determine how to prevent END, and
to improve neurologic outcome.
Key messages
1. Prior statin therapy is associated with reduced platelet
activity in patients with acute ischemic stroke.
2. Pre-treatment with statins is associated with the
severity of acute ischemic stroke.
3. Our study confirms previous studies demonstrating
that pre-existing statin use is associated with improved
clinical outcomes in acute ischemic stroke.
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